1. [Experimental therapeutic effects of hybrid liposomes on the Alzheimer's disease in vitro].
- Author
-
Zako K, Sakaguchi M, Komizu Y, Ichihara H, Goto K, Matsumoto Y, and Ueoka R
- Subjects
- Alzheimer Disease metabolism, Anions, Depression, Chemical, Humans, Liposomes therapeutic use, Tumor Cells, Cultured, Unithiol therapeutic use, Alzheimer Disease drug therapy, Amyloid beta-Peptides metabolism, Liposomes pharmacology, Neuroblastoma metabolism, Neuroblastoma pathology, Peptide Fragments metabolism, Unithiol pharmacology
- Abstract
Accumulation of β amyloid (Aβ) peptides to nerve cells should be associated with the onset of Alzheimer's disease (AD). We prepared hybrid liposomes (HL) composed of 90 mol% phospholipids having various charged head groups (cationic L-α-dimyristoyltrimethyl ammonium propane (DMTAP), anionic L-α-dimyristoylphosphatidylserine (DMPS) or zwitterionic L-α-dimyristoylphosphatidylcholine (DMPC)) and 10 mol% polyoxyethylene(23) dodecyl ether (C(12)(EO)(23))), and investigated the inhibitory effects of HL on the accumulation of Aβ(1-40) peptides into human neuroblastoma (SH-SY5Y) cells in vitro. It is noteworthy that remarkable inhibitory effects on the accumulation of Aβ(1-40) peptides were observed for SH-SY5Y cells treated with anionic HL-DMPS, though the accumulation was not inhibited by cationic HL-DMTAP. On the other hand, the immediate fusion of HL-DMTAP into SH-SY5Y cells was confirmed using a confocal laser microscope. Interestingly, the specific interactions between anionic HL-DMPS and Aβ(1-40) peptides were observed using the thioflavin T (ThT) assay. In addition, the cytotoxicity of Aβ(1-42) peptides on the SH-SY5Y cells decreased after the treatment with HL-DMPS. These results suggest that anionic HL-DMPS could be used as a novel medicine for AD in the future.
- Published
- 2011
- Full Text
- View/download PDF